');
} else {
var query = elem.find('.keywords').html();
$.ajax({
context: elem,
url: 'https://wn.com/api/upge/cheetah-search-adv/video',
cache: true,
data: {
'query': query
},
dataType: 'jsonp',
success: function(text) {
if (text.length > 0) {
video_id = text[0].id;
elem.find('.player').html('
');
}
}
});
}
}
var stopAllYouTubeVideos = function() {
var iframes = document.querySelectorAll('iframe');
Array.prototype.forEach.call(iframes, function(iframe) {
iframe.contentWindow.postMessage(JSON.stringify({ event: 'command', func: 'pauseVideo' }), '*');
});
}
jQuery(function() {
jQuery(".playVideo").live("click", function() {
if(!$(this).hasClass("played")){
stopAllYouTubeVideos();
var elem = $(this);
setTimeout(function(){
mouseOverMe(elem);
}, 1000);
}
});
jQuery(".description_box .expandContent").live("click", function() {
elem = $(this).parent().parent().parent().find('.descContent');
if(elem.height() > 51) {
elem.css('height', '44px');
$(this).html('Show More
');
}else{
elem.css('height', 'auto');
$(this).html('Hide
');
}
});
jQuery('.interview-play-off').click(function() {
$(".interview-play-off").hide();
$(".interview-play").show();
$(".videoplayer-control-pause").click();
});
jQuery(".video-desc .show_author_videos").live("click", function() {
query = $(this).attr('title');
container = $(this).parent().parent().parent().find('.video-author-thumbs');
$(this).parent().parent().parent().find('.video-author-thumbs').css('height', '220px');
jQuery.ajax({
url: '/api/upge/cheetah-photo-search/videoresults',
data: {'query': query},
success: function(text) {
if(!text) { text = i18n("No results"); }
container.html(jQuery(text));
}
});
});
});
// -->
Latest News for: inhibitor
Edit
PR Newswire
30 Mar 2026
"Our lead DNA pol IIIC inhibitor, ibezapolstat, is ready to advance to international, Phase 3, pivotal registration trials in the US and EU for oral treatment of acute C.
Edit
PR Newswire
30 Mar 2026
FPI achieved for first-in-class combination of IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor) ... In addition, IDE849 is being evaluated in a clinical combination with IDEAYA's potential first-in-class Phase 1 PARG inhibitor, IDE161.
Edit
GetNews
27 Mar 2026
DelveInsight’s “PD-1 and PD-L1 Inhibitors Competitive landscape 2026” report provides comprehensive insights about 180+ companies and 200+ drugs in the PD-1 and PD-L1 Inhibitors Competitive landscape.